167 related articles for article (PubMed ID: 30580646)
1. Pharmacodynamics of the agents used for the treatment of erectile dysfunction.
Le TV; Tsambarlis P; Hellstrom WJG
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):121-131. PubMed ID: 30580646
[TBL] [Abstract][Full Text] [Related]
2. An update on the drug safety of treating erectile dysfunction.
Gul M; Serefoglu EC
Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252
[No Abstract] [Full Text] [Related]
3. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
Hatzimouratidis K; Salonia A; Adaikan G; Buvat J; Carrier S; El-Meliegy A; McCullough A; Torres LO; Khera M
J Sex Med; 2016 Apr; 13(4):465-88. PubMed ID: 27045254
[TBL] [Abstract][Full Text] [Related]
4. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
5. Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
Afferi L; Pannek J; Louis Burnett A; Razaname C; Tzanoulinou S; Bobela W; da Silva RAF; Sturny M; Stergiopulos N; Cornelius J; Moschini M; Iselin C; Salonia A; Mattei A; Mordasini L
Andrology; 2020 Nov; 8(6):1660-1673. PubMed ID: 32741129
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
Lee M; Sharifi R
Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
[TBL] [Abstract][Full Text] [Related]
7. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
[TBL] [Abstract][Full Text] [Related]
8. A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Kloner RA; Goggin P; Goldstein I; Hackett G; Kirby MG; Osterloh I; Parker JD; Sadovsky R
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):375-386. PubMed ID: 29739235
[TBL] [Abstract][Full Text] [Related]
9. Alprostadil for the treatment of impotence.
Hanchanale V; Eardley I
Expert Opin Pharmacother; 2014 Feb; 15(3):421-8. PubMed ID: 24369066
[TBL] [Abstract][Full Text] [Related]
10. Avanafil for the treatment of erectile dysfunction.
Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for erectile dysfunction.
Eardley I; Donatucci C; Corbin J; El-Meliegy A; Hatzimouratidis K; McVary K; Munarriz R; Lee SW
J Sex Med; 2010 Jan; 7(1 Pt 2):524-40. PubMed ID: 20092451
[TBL] [Abstract][Full Text] [Related]
12. [Side effects of erectile dysfunction drug treatment].
Sperling H
Urologe A; 2017 Apr; 56(4):451-455. PubMed ID: 28251255
[TBL] [Abstract][Full Text] [Related]
13. Emerging oral drugs for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
[TBL] [Abstract][Full Text] [Related]
14. Postcoital vomiting after taking sildenafil?
Lamb M; Brahm N; Fox MD
J Fam Pract; 2013 Feb; 62(2):61-2. PubMed ID: 23405374
[No Abstract] [Full Text] [Related]
15. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
[TBL] [Abstract][Full Text] [Related]
16. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
[TBL] [Abstract][Full Text] [Related]
17. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.
Palit V; Eardley I
Nat Rev Urol; 2010 Nov; 7(11):603-9. PubMed ID: 21068761
[TBL] [Abstract][Full Text] [Related]
18. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
